Cargando…

hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target

Abnormal RNA metabolism, regulated by various RNA binding proteins, can have functional consequences for multiple diseases. Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an important RNA binding protein, that regulates various RNA metabolic processes, including transcription, alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jianguo, Zhou, Jianlong, Lin, Yunxiao, Huang, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634572/
https://www.ncbi.nlm.nih.gov/pubmed/36339596
http://dx.doi.org/10.3389/fphar.2022.986409
_version_ 1784824525785923584
author Feng, Jianguo
Zhou, Jianlong
Lin, Yunxiao
Huang, Wenhua
author_facet Feng, Jianguo
Zhou, Jianlong
Lin, Yunxiao
Huang, Wenhua
author_sort Feng, Jianguo
collection PubMed
description Abnormal RNA metabolism, regulated by various RNA binding proteins, can have functional consequences for multiple diseases. Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an important RNA binding protein, that regulates various RNA metabolic processes, including transcription, alternative splicing of pre-mRNA, translation, miRNA processing and mRNA stability. As a potent splicing factor, hnRNP A1 can regulate multiple splicing events, including itself, collaborating with other cooperative or antagonistical splicing factors by binding to splicing sites and regulatory elements in exons or introns. hnRNP A1 can modulate gene transcription by directly interacting with promoters or indirectly impacting Pol II activities. Moreover, by interacting with the internal ribosome entry site (IRES) or 3′-UTR of mRNAs, hnRNP A1 can affect mRNA translation. hnRNP A1 can alter the stability of mRNAs by binding to specific locations of 3′-UTR, miRNAs biogenesis and Nonsense-mediated mRNA decay (NMD) pathway. In this review, we conclude the selective sites where hnRNP A1 binds to RNA and DNA, and the co-regulatory factors that interact with hnRNP A1. Given the dysregulation of hnRNP A1 in diverse diseases, especially in cancers and neurodegeneration diseases, targeting hnRNP A1 for therapeutic treatment is extremely promising. Therefore, this review also provides the small-molecule drugs, biomedicines and novel strategies targeting hnRNP A1 for therapeutic purposes.
format Online
Article
Text
id pubmed-9634572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96345722022-11-05 hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target Feng, Jianguo Zhou, Jianlong Lin, Yunxiao Huang, Wenhua Front Pharmacol Pharmacology Abnormal RNA metabolism, regulated by various RNA binding proteins, can have functional consequences for multiple diseases. Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an important RNA binding protein, that regulates various RNA metabolic processes, including transcription, alternative splicing of pre-mRNA, translation, miRNA processing and mRNA stability. As a potent splicing factor, hnRNP A1 can regulate multiple splicing events, including itself, collaborating with other cooperative or antagonistical splicing factors by binding to splicing sites and regulatory elements in exons or introns. hnRNP A1 can modulate gene transcription by directly interacting with promoters or indirectly impacting Pol II activities. Moreover, by interacting with the internal ribosome entry site (IRES) or 3′-UTR of mRNAs, hnRNP A1 can affect mRNA translation. hnRNP A1 can alter the stability of mRNAs by binding to specific locations of 3′-UTR, miRNAs biogenesis and Nonsense-mediated mRNA decay (NMD) pathway. In this review, we conclude the selective sites where hnRNP A1 binds to RNA and DNA, and the co-regulatory factors that interact with hnRNP A1. Given the dysregulation of hnRNP A1 in diverse diseases, especially in cancers and neurodegeneration diseases, targeting hnRNP A1 for therapeutic treatment is extremely promising. Therefore, this review also provides the small-molecule drugs, biomedicines and novel strategies targeting hnRNP A1 for therapeutic purposes. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9634572/ /pubmed/36339596 http://dx.doi.org/10.3389/fphar.2022.986409 Text en Copyright © 2022 Feng, Zhou, Lin and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Feng, Jianguo
Zhou, Jianlong
Lin, Yunxiao
Huang, Wenhua
hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target
title hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target
title_full hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target
title_fullStr hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target
title_full_unstemmed hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target
title_short hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target
title_sort hnrnp a1 in rna metabolism regulation and as a potential therapeutic target
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634572/
https://www.ncbi.nlm.nih.gov/pubmed/36339596
http://dx.doi.org/10.3389/fphar.2022.986409
work_keys_str_mv AT fengjianguo hnrnpa1inrnametabolismregulationandasapotentialtherapeutictarget
AT zhoujianlong hnrnpa1inrnametabolismregulationandasapotentialtherapeutictarget
AT linyunxiao hnrnpa1inrnametabolismregulationandasapotentialtherapeutictarget
AT huangwenhua hnrnpa1inrnametabolismregulationandasapotentialtherapeutictarget